Carmel Biosciences Inc. is a biopharmaceutical company that develops drugs from novel compounds to mitigate risk factors in the cardiovascular & metabolic disease continuum. The company also has a Phase II-IV clinical research facility. Carmel Biosciences owns or has rights to three provisional patents for compounds within its pipeline. Our products are developed through intelligent drug design to target common molecular pathways for complex multi-factorial disease.